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Background: Recently published results of quality of life (QoL) studies indicated different outcomes of palliative
radiotherapy for brain metastases. This prospective multi-center QoL study of patients with brain metastases was
designed to investigate which QoL domains improve or worsen after palliative radiotherapy and which might
provide prognostic information.
Methods: From 01/2007-01/2009, n=151 patients with previously untreated brain metastases were recruited at 14
centers in Germany and Austria. Most patients (82 %) received whole-brain radiotherapy. QoL was measured with
the EORTC-QLQ-C15-PAL and brain module BN20 before the start of radiotherapy and after 3 months.
Results: At 3 months, 88/142 (62 %) survived. Nine patients were not able to be followed up. 62 patients (70.5 % of
3-month survivors) completed the second set of questionnaires. Three months after the start of radiotherapy QoL
deteriorated significantly in the areas of global QoL, physical function, fatigue, nausea, pain, appetite loss, hair loss,
drowsiness, motor dysfunction, communication deficit and weakness of legs. Although the use of corticosteroid at
3 months could be reduced compared to pre-treatment (63 % vs. 37 %), the score for headaches remained stable.
Initial QoL at the start of treatment was better in those alive than in those deceased at 3 months, significantly for
physical function, motor dysfunction and the symptom scales fatigue, pain, appetite loss and weakness of legs. In a
multivariate model, lower Karnofsky performance score, higher age and higher pain ratings before radiotherapy
were prognostic of 3-month survival.
Conclusions: Moderate deterioration in several QoL domains was predominantly observed three months after start
of palliative radiotherapy for brain metastases. Future studies will need to address the individual subjective benefit
or burden from such treatment. Baseline QoL scores before palliative radiotherapy for brain metastases may contain
prognostic information.
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Quality of life (QoL) is now considered an important
endpoint in oncological studies and is essential for the
assessment of different therapeutic options. Knowledge
about health-related QoL could help physicians, patients
and even family members to achieve a better under-
standing of the treatment outcomes of cancer patients
and make appropriate decisions. In the literature contro-
versial results of measurement of QoL in patients with
brain metastases have been reported [1-5]. Differences
may have been caused by diverse points of time of as-
sessment and the variety of fractionation schemes and
patient cohorts. These results led us to address prospect-
ively the question of the development of QoL over time
within three months after initiation of palliative radio-
therapy for brain metastases.
Physicians often estimate survival of patients much
more positively than is realistic, potentially resulting in
aggressive therapies without benefit [6,7]. The most
commonly used instrument to estimate survival object-
ively in patients with brain metastases is the recursive
partitioning analysis (RPA) [8,9] which relates overall
survival after whole-brain radiotherapy (WBRT) to Kar-
nofsky performance status (KPS), extracranial tumour
status and age [10,11]. The more recently proposed
graded prognostic assessment (GPA) included the num-
ber of brain metastases [12]. Rades et al. published a
new scoring system to predict the survival of these
patients treated with WBRT [11] and added the interval
from tumour diagnosis to WBRT (longer time is better)
to the criteria of RPA. They suggested an approach in
which more favourable patients could be treated with
longer-course WBRT to reduce neurotoxicity and other
patients with poor prognosis could benefit from short-
course WBRT.
Results of our prospective quality-of-life pilot study [1]
indicated, that the initial QoL at start of radiotherapy
was better in patients found to be alive at 3 months than
in those deceased within 3 months. We therefore
hypothesized that QoL at initiation of radiotherapy, may
be an independent prognostic factor for survival of
patients with brain metastases. Additionally, we ob-
served a worsening of QoL in most domains in the pilot
study, significant in drowsiness, hair loss and weakness
of legs, during the first three months after the start of
palliative radiotherapy for brain metastases. Other stud-
ies showed similar results with statistically significant
deteriorations in fatigue [3], drowsiness and appetite [5]
after the delivery of palliative radiotherapy for brain
metastases.
Because our pilot study was limited by the small num-
ber of only n = 17 patients providing QoL data at the 3-
month time point, we performed a follow-up large-scale
study to address the following questions:Which pre-treatment QoL domains and symptom
scales increased or decreased significantly after
3 months? Which clinical characteristics influence the
QoL after 3 months? What could be a benefit of
radiotherapy?
Which pre-treatment QoL scales of the 3-month-
survivors are significantly different from those of the
non-survivors and could be a prognostic factor?
Methods
Recruitment
Patients with previously untreated brain metastases of
solid tumours were recruited at 14 radiation oncology
centres. Exclusion criteria were language barriers, insuf-
ficient compliance or cognitive status and chemotherapy
during planned radiotherapy. After informed consent
questionnaires EORTC QLQ-C15-PAL and BN20 were
handed out to patients at the time of the initial consult-
ation for the planned palliative brain radiotherapy. Pa-
tient and treatment characteristics, KPS and Barthel
Index [13], a scale summarizing the ability to perform
activities of daily living, were collected using patient
records and documented follow up. Three months after
the first radiotherapy session, survival status of patients
was determined. We called patients by telephone and
asked about their situation and performance. After that
(if it was ethical), we sent out questionnaires with a
stamped self-addressed envelope. If patients came for
follow-up visits at the clinic, we also used this as an op-
portunity to hand out the questionnaire.
Ethics approval was obtained from the ethics commit-
tee at the University of Würzburg, Germany.
Quality-of-life questionnaires
QLQ-C15-PAL and BN20 validated instruments were
developed by the European Organization for Research
and Treatment of Cancer (EORTC) Quality of Life Study
Group for measuring the QoL of cancer patients in clin-
ical trials [14]. QLQ-C15-PAL is a shortened form of
QLQ-C30 for use in a palliative care setting, containing
15 items for the following nine domains: physical func-
tion, emotional function, global QoL, pain, fatigue, appe-
tite, dyspnea, constipation and sleep. Each item is scored
from 1 to 4 (00not at all00: 1; 00a little00: 2; 00quite a bit00 : 3;
00very much00:4). As an exception, global QoL is scored
from 1 (00very poor00) to 7 (00excellent00). The results for
these domains are directly comparable between QLQ-
C30 and QLQ-C15-PAL [15].
The BN20 questionnaire is a brain-specific module to
be used in conjunction with the generic EORTC ques-
tionnaires and contains 20 items grouped into four
domains (future uncertainty – four items, visual dis-
order, motor dysfunction and communication deficit –
each three items) as well as seven single items
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weakness of legs, bladder control).
Questionnaire data were processed according to the
procedures outlined in the EORTC QLQ-C30 scoring
manual and the addendum for scoring of QLQ-C15-PAL
[15,16]. For functional scales and global QoL, high
scores represent good functioning/ good QoL. For the
symptom scales and for all scales of BN20, high scores
indicate severe symptoms.
We asked proxies of patients to simultaneously partici-
pate in a separate questionnaire to report the QoL of
their relative. Results of the proxy assessment in the
main study will be published separately.
Statistical analysis
The ratings of each item of both questionnaires were
linearly transformed to a 0–100 scale, with ‘not at all’
conforming to 0 and ‘very much’ conforming to 100
[15]. QoL scores were then analyzed parametrically [17].
Mean change in scores about 10 to 20 (“moderate”) and
greater than 20 (“worse”) were considered clinically rele-
vant [18].
Means, mean differences, SEs, test statistics and p-
values for all QoL subscales, separate for time points
and patient groups, were calculated.
Paired t-tests were used to compare the patients´
mean scores between the points in time. For each scale,
a multiple regression analysis was used to find the best
prediction equation for the change of QoL ratings after
three months. The following variables were included in
the analysis: pre-therapeutic KPS, age, number of cere-
bral metastases [1–3 vs. >3], therapeutic strategy
[WBRT vs. SRS/hfSRT], localization [breast, lung, other],
and pre-therapeutic status of the primary tumour [pro-
gressive vs. non-progressive]. Dummy variables were
created for all nominal variables with more than two cat-
egories. Variables without significant influence were
excluded backwards. This method avoids insignificant
predictors and can exclude intercorrelated predictors.
Student’s t-tests for independent samples were used to
test differences in the QLQ scales between 3-month-
survivors and non-survivors. A multiple logistic regres-
sion model was used to test which variables can signifi-
cantly predict 3-month survival. The QoL scales with
significant change in the pilot study (physical function,
fatigue, pain, motor dysfunction, weakness of legs, com-
munication deficit and headaches), and the mentioned
non-QoL independent variables (number of brain metas-
tases, extracranial primary tumour situation or extracra-
nial metastases, KPS, age, primary tumour) were
included in the analysis. Variables without significant in-
fluence were excluded stepwise backwards.
The significance level was set to .05. For further ex-
plorative analyzes, the significance level was set to .01 toadjust for multiple comparisons (several scales and
groups).
Results
Patients and treatment characteristics
Including patients of the pilot study (n = 64) [1] 151
patients with previously untreated brain metastases were
recruited at 14 centres in Germany and Austria from 01/
07 to 01/09. Most patients were recruited in only few (6)
centres with 10 to 50 patients. Other centres were only
small and recruited only few patients with brain metas-
tases. The dominant radiotherapy strategy (n = 131,
88.5 %) was whole-brain radiotherapy (WBRT) alone.
Eight patients additionally received boost irradiation, 17
(11.5 %) patients stereotactic radiosurgery (SRS), hypo-
fractionated stereotactic radiotherapy (hfSRT) or 3D-
conformal local radiotherapy alone.
Patient and treatment characteristics, including the
pre-treatment KPS and the Barthel index are presented
in Table 1. The survival status was known in 142
patients, 54 (38 %) had died within three months (until
90 days) after beginning of radiation therapy. Median
overall survival was 135 days (4.5 months), 5.6 months
for patients with limited (1–3) brain metastases and
3.4 months of patients with multiple brain metastases.
Completion of questionnaires
All 151 patients completed baseline QoL questionnaires
EORTC QLQ-C15-PAL; 149 patients the BN20. 66
patients completed questionnaires at both time points.
53 of them were returned after 3 months (range 60–
120 days from initiation of radiotherapy). One patient
filled in the second questionnaire 70 days after start of
radiotherapy and died on day 87. The response rate of
3-month survivors (>90 days) was 62 of 88 (70.5 %).
QoL after 3 months in comparison to pre-treatment
Self-assessed QoL was compared for the time points be-
fore and three months after the start of radiotherapy, in-
cluding only data from patients who completed
questionnaires both at the start of radiotherapy and after
3 months, to eliminate a potential bias resulting from a
selection of survivors at the latter point of time.
Explorative analysis regarding the QLQ-C15-PAL
scales revealed a significant deterioration in global QoL
(p = 0.011), physical function (p< 0.001), fatigue (p
< 0.001), pain (p = 0.034), nausea (p< 0.001), and appe-
tite loss (p< 0.001). In the organ-specific BN20 module,
a significant deterioration in drowsiness (p< 0.001),
motor dysfunction (p = 0.014), communication deficit
(p = 0.025) and weakness of legs (p< 0.001) was noted,
whereas a trend was observed for increased hair loss
(p = 0.068) and the score for headache remained un-
changed (Figures 1a-b).
Table 1 Baseline clinical and treatment characteristics of patients registered for prospective QoL assessment
age [years] median (range) 61 (33–84)
total n = 151 100 %
primary tumor non-small cell lung cancer 70 46
small-cell lung cancer 20 13
melanoma 12 8
renal cell carcinoma 7 5
colorectal cancer 3 2
breast cancer 25 17
others 12 8
unknown 2 1
Karnofsky performance score ≥ 70 119 79
< 70 30 20
unknown 2 1









Barthel index 90-100 115 76
<90 34 23
unknown 2 1
fractionation of whole-brain radiotherapy 10x3 Gy 80 53
14x2.5 Gy 12 8
others 32 21
unknown 5 3
fractionation of stereotactic radiotherapy 1x18-20 Gy 10 7
7x5 Gy 4 3
5x6 Gy 4 3
10x4 Gy 1 1
initial steroid dose(prednisone equivalent) no steroids 41 27
daily dose <50 mg 38 25
daily dose 50–100 mg 38 25
daily dose >100 mg 26 17
unknown 8 5
extracranial tumor status primary tumor (PT) not detectable 54 36
PT detectable, not progressive 44 29
PT progressive 48 32
PT status unknown 5 3
any extracranial metastases 104 70
intracranial tumor status >3 metastases 83 56
1-3 metastases 65 44
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Table 1 Baseline clinical and treatment characteristics of patients registered for prospective QoL assessment
(Continued)
number of metastases unknown 4 3
largest metastasis >2 cm 53 35
diameter of metastases unknown 17 12
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lower at the second point of time (63 % vs. 37 %,
p = 0.002).
The therapeutic strategy (WBRT only: worse function,
p = 0.041), and the localization of the primary tumour
(breast: better function, p = 0.025) were significantly
associated with the physical function score after three
months. The therapeutic strategy (WBRT worse than
SRS/hfSRT) was significantly associated with the fatigue
score after three months (p = 0.001).
The initial KPS score was significantly associated with
the motor dysfunction (p = 0.004).
In several QoL domains, the baseline scores before
treatment were significant predictors for the scores of





Figure 1 Self-assessed QoL in preselected QLQ scales before
and 3 months after start of RT. a) EORTC QLQ C15-PAL: global
QoL, physical function (higher score better), and fatigue (higher
score worse). b) EORTC BN20: motor dysfunction, headaches and
hairloss (all higher score worse) (*p< .05, ** p< .01, ***p< .001;
paired-t-test, one-tailed).< 0.001, physical function p= 0.006, fatigue p< 0.001,
motor dysfunction p = 0.001, headache p = 0.036).
Baseline QoL as prognostic factor for survival
Baseline pre-treatment scores of physical function
(p = 0.001), fatigue (p = 0.035), pain (p = 0.01), motor dys-
function (p = 0.014), and weakness of legs (p = 0.006)
were significantly better in 3-month survivors than in
non-survivors (Figure 2a-b). However, no significant dif-
ferences were detected in the remaining preselected
domains of communication deficit and headache. Ex-
plorative analysis regarding the other QLQ-C15 PAL/
BN20 scales revealed a significant difference at baseline
between 3-month survivors and non-survivors in the






Figure 2 Differences in pre-treatment QoL between 3-month
surviviors vs. non-survivors. a) EORTC QLQ-C15-PAL: physical
function (higher score better), fatigue and pain (both: higher score
worse). b) EORTC BN20: motor dysfunction, headaches and hairloss
(higher score worse) (*p< .05, ** p< .01, ***p< .001; paired-t-test,
one-tailed).
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found three significant predictors of 3-month survival.
Patients with higher age (p = 0.04), lower KPS scores
(p = 0.001), and higher pain scores (QLQ-C15-PAL
score, p = 0.04) were found more frequently in the group
of non-survivors.Discussion
This prospective study generated a large QoL data set
related to the radiotherapy of brain metastases with a
validated brain-specific QoL questionnaire. Only one
study group reported on a bigger patient group of 170,
but used a general QoL tool (ESAS – Edmonton Symp-
tom Assessment Scale) without a brain-specific module
[5].
Three smaller trials used the Functional Assessment of
Cancer therapy – General scale (FACT-G) with a brain
module (FACT-BR) [19-21]. The results are not compar-
able to our study because of the addition of temozolo-
mide to WBRT [19] or different evaluation points of
time. The brain module BN20 has been validated by the
EORTC in an international study incorporating 891
patients with primary brain tumours [22] and has been
applied in some smaller QoL studies of patients with
brain metastases [4,23,24]. Because of short assessment
periods [4,15] after radiotherapy or analysis only of spe-
cial radiation techniques like radiosurgery these studies
are not directly acceptable to the routine palliative radio-
therapy setting with predominant whole-brain radiother-
apy and short survival times.
The BN20 questionnaire was used in this study with
the shortened questionnaire variant EORTC QLQ-C15-
PAL to reduce the burden of repeated questionnaire
completion for the incurable patients. It should be noted
that the short version QLQ-C15-PAL lacks the two
questions regarding cognitive function from QLQ-C30
[15], and therefore some potentially interesting informa-
tion was lost by the decision for the shorter version.
QoL was evaluated at only two points in time. The
second point of time after 3 months was chosen to re-
duce the effects of rapid deterioration by very early
tumour progression, while maintaining a reasonable
number of patients available for assessment. It must be
acknowledged that the addition of both earlier and later
points of time would have been informative. However, a
distinction between brain-metastasis-related, extracranial-
tumour-related and treatment-related impairment would
probably have been similarly problematic at other points
of time. The choice of the 3-month-point was a com-
promise for pragmatic reasons. Given all the problems
associated with the highly palliative situation of the
patients studied, a response rate of 70 % of survivors at
this point of time appears adequate.The overall survival in the patient group (38 % dead at
three months) is comparable to other reports [3]. Previ-
ously, improved survival in patients with brain metasta-
ses has been linked to lower RPA class [10], higher GPA
scores [25,26], with stable extracranial tumour situation,
limited (1–3) intracranial metastases and therefore pos-
sible radiosurgery [27,28] and low steroid dose [29].
One of the most important results of this study was
the deterioration of different domains and symptom
scales of QoL in patients after three months. This was
acceptable in potentially treatment-related symptom
scales such as hair loss (only a trend in this study) and
fatigue. In our study 42 % and 54.2 % of patients showed
an increase of hair loss and fatigue scores, respectively,
over 20 points. This can be considered clinically rele-
vant. The study of Slotman et al. [17] examined QoL of
patients with or without prophylactic cranial irradiation
(PCI) for small-cell lung cancer with the same question-
naires. Slotman et al. [17] found a worsening hair loss (≥
20 points) in 22.4 % of patients with PCI and 12.2 % of
controls and a worsening of fatigue on this order of
magnitude in 49 % of patients with PCI and 26.7 % of
controls. Hair loss and fatigue are both also potential
chemotherapy-associated symptoms. In our study subse-
quent chemotherapies after irradiation were not evalu-
ated. Our findings are comparable with the results of
Wong et al. who reported more severe fatigue symptoms
in 57 % of patients over time [3]. The testing of influen-
cing factors in our study showed a significant association
of WBRT as treatment strategy and the fatigue score
after three months.
The score for headache was slightly better after
3 months in the pilot phase of this study and remained
unchanged in the now reported main phase with a larger
cohort of patients. Additionally, the steroid use after
3 months was significantly lower. Therefore, these
results show one important benefit of the radiotherapy.
The deterioration of global health status, physical
function and of symptom scales like motor dysfunction,
communication deficit or weakness of legs after three
months were not necessarily expected. The most import-
ant aim of brain irradiation in patients with brain metas-
tases should be the improvement or stabilization of the
performance status and of QoL.
Intracranial and extracranial progression or adverse
treatment effects are potential explanations for the de-
terioration of QoL within three months after start of
radiotherapy. Further published QoL studies did not
analyze intra- or extracranial progression over time. This
study provided some limited information on progression
of the primary, additional extracranial and intracranial
metastases or increase in the size of brain metastases.
Due to the poor condition of most patients, it was felt to
be unethical to require specific imaging studies to be
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radiotherapy was available for 53 % of patients and
showed intracranial progression in 20 % and extracranial
progression in 53 % of patients among these patients.
For specific preselected QoL domains, predominant fac-
tors influencing the scores at the 3-month-point were
identified. For instance, brain metastases from breast
cancer were associated with better physical function at
3 months. This may be related to the known slightly bet-
ter prognosis after radiotherapy for patients with brain
metastases from breast cancer compared to other pri-
maries [30] but also to the more recently documented
improved outcome of subgroups e. g. with positive Her-
2 status [31].
A known prognostic factor in brain metastases
patients, KPS, was associated with motor dysfunction
after three months. The therapeutic strategy (WBRT vs.
stereotactic radiotherapy) was significantly associated
with the physical function score during the same period.
Although the limited information on imaging response
of brain metastasis precludes definitive conclusions, fac-
tors related to the initial selection of patients for specific
strategies (e. g. stereotactic radiotherapy for fitter
patients with limited number of metastases) are likely to
explain part of the variation in post-radiotherapy QoL.
Data from the literature suggests that achieving local
control of brain metastases is a prerequisite for main-
taining neurologic function[32]. Therefore, patients trea-
ted with palliative whole-brain radiotherapy alone may
deteriorate not because of, but despite of radiotherapy,
not considering the frequent rapid extracranial progres-
sion of metastases.
A second main result of this study was the difference
of baseline QoL of 3-month survivors vs. non-survivors.
Baseline pre-treatment QoL scores of physical function,
fatigue, pain, appetite loss, motor dysfunction, weakness
of legs were significantly better in survivors suggesting
that these scores might contain prognostic information.
Similar results were presented by Movsas et al. who
analyzed the QoL of 239 patients with locoregionally
advanced non-small-cell lung cancer treated with ami-
fostine and chemotherapy using the EORTC QLQ-C30
and LC-13 (RTOG 9801) [33]. Patients with a global
QoL score less than 66.7 had an approximately 70 %
higher rate of death than patients with scores of ≥66.7
(p = 0.012). Other QoL predictors for OS were physical
functioning and dyspnoea. In their study, these QoL
scales seemed to be more relevant and powerful as prog-
nostic factors than standard measures like KPS, so the
authors suggested patient-reported QoL as a good strati-
fication factor in future.
Other prior studies with lung cancer patients, who
were also a predominant subgroup in the present cohort,
have shown similiar results. Montezari et al. reportedthe initial global QoL as the most significant predictor
of survival at 3 months [34]. In the literature, global
QoL, appetite loss, fatigue and pain were the most im-
portant indicators for predicting survival times in cancer
patients after adjusting known clinical prognostic factors
[35,36]. It is argued that measures such as global QoL
are patient-rated and thus have the potential to reflect
the patient's well-being better than physician's observed
indicators. Patient-reported outcomes detect prognostic-
ally relevant lowered patient well-being earlier than
other measures. Higher scores correlate with more posi-
tive behaviour and reflect individual characteristics that
affect survival [36]. Data for high-grade glioma patients
defined fatigue as a prognostic factor [37] but no other
trial has so far shown a specific QoL score of patients
with brain metastases as predictive.
In the present study, using a multiple logistic stepwise
regression model, only pain as one of six predetermined
QoL domains, when tested together with clinical vari-
ables, remained prognostically significant. KPS and age
were also significant predictors of survival. One possible
explanation is that the KPS, as a global performance
measure, contains information overlapping with that of
the selected QoL domains. It could be argued that KPS
alone integrates some of the prognostically relevant in-
formation obtainable from the QoL questionnaires. The
prognostic role of pain, as assessed by EORTC QLQ-
C15-PAL, for survival may be that on an indicator of un-
controlled extracranial disease. Sundaresan et al. devel-
oped a prognostic index for patients with WBRT for
brain metastases of lung cancer and scored the factors
age, ECOG performance status, histology, weight loss,
primary and systemic disease status [38]. The new scor-
ing system suggested by Rades et al. predicted the sur-
vival of all patients with brain metastases treated with
WBRT [11]. Actuarial 6-month survival varied from 6 %
of patients in the worst prognostic group, via 15 % and
43 % to 76 % of patients with better status. No QoL
scores were used because of the retrospective nature of
these studies. Sperduto et al. defined a disease-specific
GPA, because patients with brain metastases are a het-
erogeneous population and different primaries are not
comparable [26].
Potentially, the inclusion of self-reported QoL scores
in prognostic scoring systems for patients with brain
metastases may be more relevant within more specific-
ally defined patients subgroups, e. g. only lung cancer or
breast cancer patients. Given the generally unsatisfactory
QoL outcomes after palliative radiotherapy for brain me-
tastases, novel strategies to improve intracranial tumour
control are needed. Further QoL studies are necessary to
better identify patients groups who may benefit from
specific modes of radiotherapy, e. g. shorter or longer-
course WBRT, local (stereotactic) treatment alone or
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very poor baseline characteristics (including clinical and
QoL parameters) may be defined, in whom radiotherapy
can be withheld.
Conclusions
In a prospective study, QoL of patients with brain metastases
deteriorated in several domains within three months of initi-
ation of palliative radiotherapy. However, headache remained
unchanged and steroid use decreased at 3 months compared
to baseline. Although 3-month survivors differed in several
areas of pre-treatment QoL scores from non-survivors, only
the QoL score for pain was predictive of survival when clin-
ical variables were also considered.
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